EGFR is overexpressed in several tumor types, including head and neck, breast, renal, non-small cell lung, colorectal, ovarian, pancreatic, and bladder cancers, thus triggering an early interest in EGFR-targeting therapies [3]. The gene discussed is EGFR; the disease is urinary bladder cancer.